MYDA Advisors’s Capricor Therapeutics CAPR Stock Holding History

MYDA Advisors’s Portfolio CAPR Stock Details CAPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-24,000	Closed	-$365K	–	148
2024 Q3	$365K	Buy	+24,000	New	+$119K	0.08%	119

Other funds holding CAPR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

Altium Capital Management New York $42M AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

MYDA Advisors's CAPR Position: Q4 2024 in Review

MYDA Advisors sold out of Capricor Therapeutics (CAPR) in Q4 2024, closing a stake of 24,000 shares — an estimated $365K sold.

MYDA Advisors first reported a position in CAPR in Q3 2024 and held it in 1 quarter. The position peaked at $365K in Q3 2024. 108 funds tracked by Wall St. Rank hold CAPR as of Q4 2024.

MYDA Advisors reported no remaining Capricor Therapeutics position as of Q4 2024 after selling out during the quarter.
MYDA Advisors sold 24,000 Capricor Therapeutics shares in Q4 2024, an estimated $365K.
MYDA Advisors first reported a position in Capricor Therapeutics in Q3 2024 and held it in 1 quarter.
MYDA Advisors's Capricor Therapeutics position peaked at $365K in Q3 2024.
108 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q4 2024.

Based on MYDA Advisors's 13F filing for Q4 2024, filed 13 Feb 2025.